Released Aug 14, 2025, before the open
10-Q filed Aug 14, 2025, 45 days after period end · 0001785530-25-000021
Q2 2025 · 10-Q
Revenue—
Net Income-$17.98M-$17.98M N/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.40-$0.40 N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$17,542,000N/M
Operating Cash Flowderived-$15,164,000N/M
Free Cash Flowderived-$15,164,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Net Income | -$17.98M | -$17.25M | -$5.10M | -$14.59M |
| EPS Diluted | -$0.40 | -$0.43 | -$0.14 | -$0.53 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR